Oncology · Gastric CancerTrial Updateclinicalmid-term

Phase Ib Trial of Aldesleukin with Nivolumab for Gastric Cancer with Peritoneal Metastasis

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/30/2026, 6:30:58 PM

Assessment confidence: 55% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing phase Ib trial of aldesleukin in combination with nivolumab and standard chemotherapy represents a potential advancement in the treatment of gastric cancer with peritoneal metastasis. This combination therapy could reshape treatment paradigms and influence competitive positioning in a challenging oncology market. Regulatory context from FDA (Ongoing | Cancer Accelerated Approvals) supports the near-term read. Assessment grounded in 23 ranked evidence items (5 high-relevance).

Strategic Assessment

Portfolio teams should assess the potential of this combination therapy to enhance treatment outcomes in gastric cancer, influencing future development strategies. The strongest clinical anchor is Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis (ClinicalTrials.gov), entity match (nivolumab). In Oncology · Gastric Cancer, 4 regulatory and 4 competitive items passed relevance filtering for nivolumab.

Competitive Pressure

The most relevant competitive pressure comes from Cabozantinib plus Nivolumab Shows Promise in Advanced Non-Clear Cell RCC (Humanexa Signals) — entity match (nivolumab). Secondary pressure from Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC. This trial may position the combination therapy as a novel treatment option in a challenging indication, potentially impacting existing therapies.

Regulatory Outlook

Regulatory risk is concentrated around Ongoing | Cancer Accelerated Approvals (FDA). Regulatory pathway relevance (indication). The trial results will inform future regulatory submissions, potentially leading to new treatment approvals that could alter the landscape of gastric cancer therapies.

Key Risks

Elevated medium regulatory exposure for nivolumab could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If successful, this combination therapy could capture market share from existing treatments, enhancing revenue potential in the gastric cancer segment.
Upside for nivolumab may improve if Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis (ClinicalTrials.gov) delivers favorable follow-through.
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have postmarketing requirement(s) for ongoing clinical trial(s) to verify clinical benefit.
Oncology · NSCLC · Trial Update · These results position LORBRENA as a preferred standard of care over XALKORI in ALK-positive advanced NSCLC, potentially shifting treatment paradigms.
FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to Drugs@FDA for the latest approvals and prescribing information for specific products.

What Would Change This Assessment

This becomes more urgent if Monitor trial results for efficacy and safety, as well as subsequent regulatory decisions based on outcomes.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
Outcome from Ongoing | Cancer Accelerated Approvals would change the regulatory/clinical read.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Ongoing | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (indication)
FDA document
View source
Withdrawn | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (indication)
FDA document
View source
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Janus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis
ClinicalTrials.govhigh relevance
Entity match (nivolumab)
FDA document
View source
Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Phase I Trial of DNA-PK Inhibitor (PEPOSERTIB ) in Combination With Radiation and Adjuvant Temozolomide in Newly Diagnosed MGMT Unmethylated and Recurrent Glioblastoma
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Cabozantinib plus Nivolumab Shows Promise in Advanced Non-Clear Cell RCC
Humanexa Signalshigh relevance
Entity match (nivolumab)
Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC
Humanexa Signalshigh relevance
Sponsor/company relevance (Pfizer)
Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalsmedium relevance
Sponsor/company relevance (Roche)
Bristol-Myers Squibb Evaluates Pumitamig vs Pembrolizumab in NSCLC Trial
Humanexa Signalsmedium relevance
Moderate corpus alignment

Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
The role of capacitive hyperthermia as an adjunct treatment in oncology: a systematic review of randomized phase III trials.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
FTO-mediated m(6)A demethylation of BCL6 promotes gastric cancer progression by suppressing ferroptosis.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
RBM15B-mediated m6A modification of FOXM1 activates the AURKA/TPX2 axis to promote epithelial-mesenchymal transition-driven endometrial cancer progression.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Sentinel Lymph Node Mapping with Indocyanine Green in Endometrial Cancer: Does the Minimally Invasive Platform Matter?
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
In vitro screening of compounds for targeting gastric cancer with Y220C p53 mutation: a molecule combining zinc chelation and Michael acceptor drives CDKN1 and BBC3 expression to restore a p53-depende
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

nivolumab

Commercial impact

medium

If successful, this combination therapy could capture market share from existing treatments, enhancing revenue potential in the gastric cancer segment.

Regulatory impact

medium

The trial results will inform future regulatory submissions, potentially leading to new treatment approvals that could alter the landscape of gastric cancer therapies.

What to watch

Monitor trial results for efficacy and safety, as well as subsequent regulatory decisions based on outcomes.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.